COVID-19. TO MANUFACTURE AND EVALUATE THE SAFETY, EFFICACY AND TOLERABILITY OF GALIDESIVIR A BROAD SPECTRUM, ANTIVIRAL THERAPEUTIC.

DEFINITIVE CONTRACT won by BIOCRYST PHARMACEUTICALS INC · work in DURHAM, NC
$6,326,480
RecipientBIOCRYST PHARMACEUTICALS INC UEI MGXADJ6SCLJ5
Award ID75N93020C00055
Award amount$6,326,480
Award typeDEFINITIVE CONTRACT
Awarding agencyDepartment of Health and Human Services — National Institutes of Health
NAICS541715 — RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)
PSCAJ12
Set-asideUnrestricted
Start dateSep 1, 2020
End dateSep 30, 2022
Place of performanceDURHAM, NC
Record updatedMay 27, 2022

View the official award record

More awards won by BIOCRYST PHARMACEUTICALS INC

IGF::OT::IGF - DEVELOPMENT OF MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES, BASE, OPTION 1 AND OPTION 2 AWARD, 09/16/2013 - 09/15/2017
Department of Health and Human Services · $47,755,723 · Sep 16, 2013
PERAMIVIR, RAPIVAB FLU TREATMENT
Department of Health and Human Services · $34,660,000 · Sep 1, 2018
PERAMIVIR (RAPIVAB 200MG/20ML (10MG/ML INJ SOLN))
Department of Health and Human Services · $13,877,674 · Sep 30, 2024
BULK ORLADEYO PHARMACEUTICAL
Department of Veterans Affairs · $394,853 · Mar 12, 2025
BULK ORDER ORLADEYO
Department of Veterans Affairs · $385,448 · Mar 12, 2024

Our catalog shows awards with a value or ceiling of $250K+ active within the last 5 years. Need older history or smaller awards? Tell us what you need — we expand by request.

Awards tell you who won. Bids tell you what's next. BidCatch scans 100+ federal, state, and local sources every night and sends the new opportunities matching your trade — before they're awarded to someone else. $0 today for 14 days (card required), then $49.99/month.

Search open bids